Cardiovascular News’ top 10 stories of March 2023


The news agenda in March was dominated by late-breaking data from the American College of Cardiology (ACC) 2023 Scientific Session (4–6 March, New Orleans, USA), where there were practice-changing updates in the fields of coronary intervention, transcatheter tricuspid therapy and mitral surgery, among many others.

  1. REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI
    Assessing myocardial viability does not aid the selection of patients who will benefit—or not—from percutaneous coronary intervention (PCI) for the treatment of severe ischaemic cardiomyopathy. This is according to the findings of an analysis of the REVIVED-BCIS-2 trial, in which investigators assessed the effect of myocardial viability, functional recovery and PCI on clinical outcomes in the trial.
  2. Quality of life improvements drive benefit for transcatheter therapy in TRILUMINATE pivotal trial
    Hotly-anticipated results of the randomised TRILUMINATE pivotal trial indicate that transcatheter repair in symptomatic tricuspid regurgitation (TR) patients using the Triclip (Abbott) system was effective in reducing TR and led to improvements in quality of life at one year.
  3. Benefit of TAVI “consistent” over first three years in low risk patients
    Three-year results from the Evolut Low Risk trial have shown “durable” benefits of transcatheter aortic valve implantation (TAVI) compared to surgery regarding all-cause mortality or disabling stroke in patients at low surgical risk.
  4. MitraClip meets endpoints at five years in COAPT trial
    Final, five-year clinical outcomes from the COAPT trial, evaluating transcatheter mitral valve repair with the first-generation MitraClip (Abbott) device in patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation (MR), indicate that the interventional treatment led to a lower rate of heart failure hospitalisation and all-cause mortality when compared to medical therapy alone.
  5. Five-year durability analysis of CoreValve and Evolut platforms “underscores long-term promise of TAVI”
    Five-year bioprosthetic valve dysfunction data for Medtronic’s CoreValve and later-generation Evolut transcatheter aortic valve implantation (TAVI) platforms have been presented at the 2023 Cardiovascular Research Technologies (CRT) conference (25–28 February, Washington DC, USA).
  6. Intravascular imaging bests angiography guidance in trial of PCI in complex lesions
    Use of intravascular imaging guidance for percutaneous coronary intervention (PCI) in patients with complex coronary artery lesions led to a lower risk of a composite of death from cardiac causes, target vessel-related myocardial infarction (MI) or clinically driven target revascularisation than procedures using only angiography.
  7. Equivalent recovery times shown between minimally invasive and conventional surgery for mitral valve repair
    The largest randomised controlled trial to date to compare minimally invasive and conventional cardiac surgery in the mitral valve—UK Mini Mitral—has found surgical outcomes and quality of life to be similar in patients who received either technique for mitral valve repair at 12 weeks post-procedure.
  8. Neovasc shareholders approve acquisition by Shockwave Medical
    Neovasc has announced that its shareholders have approved the previously-announced acquisition of all of the outstanding common shares of the company by Shockwave Medical by way of a statutory plan of arrangement at the special meeting of shareholders held today this week.
  9. EU ministers approve changes to MDR transition timetable
    The European Union’s Council of Ministers has today adopted a resolution to extend the deadline for the certification of medical devices under the Medical Devices Regulation (MDR).
  10. Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial
    A new trial of endovascular ultrasound-based renal denervation technology has found that it reduced blood pressure in hypertensive patients at two months.


Please enter your comment!
Please enter your name here